Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;4(7):e488.
doi: 10.1016/S2666-5247(23)00102-7. Epub 2023 Apr 20.

Mucosal immune responses following a fourth SARS-CoV-2 vaccine dose

Oscar Bladh  1 , Ulrika Marking  1 , Sebastian Havervall  1 , Nina Greilert Norin  1 , Katherina Aguilera  1 , Sophia Hober  2 , Anna Smed-Sörensen  3 , Max Gordon  1 , Kim Blom  4 , Mikael Åberg  5 , Jonas Klingström  6 , Charlotte Thålin  7
Affiliations

Mucosal immune responses following a fourth SARS-CoV-2 vaccine dose

Oscar Bladh et al. Lancet Microbe. 2023 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

This study was supported by grants from the Jonas and Christina af Jochnick Foundation, Region Stockholm, SciLifeLab, the Knut and Alice Wallenberg Foundation, the Leif Lundblad Family Foundation, the Swedish Research Council, the Swedish Heart and Lung Foundation, the Bill & Melinda Gates Foundation, and the Center for Innovative Medicine. We declare no competing interests.

References

    1. Havervall S, Marking U, Svensson J, et al. Anti-spike mucosal IgA protection against SARS-CoV-2 omicron infection. N Engl J Med. 2022;387:1333–1336. - PMC - PubMed
    1. Cagigi A, Yu M, Österberg B, et al. Airway antibodies emerge according to COVID-19 severity and wane rapidly but reappear after SARS-CoV-2 vaccination. JCI Insight. 2021;6 - PMC - PubMed
    1. Nordström P, Ballin M, Nordström A. Effectiveness of a fourth dose of mRNA COVID-19 vaccine against all-cause mortality in long-term care facility residents and in the oldest old: a nationwide, retrospective cohort study in Sweden. Lancet Reg Health Eur. 2022;21 - PMC - PubMed
    1. Regev-Yochay G, Gonen T, Gilboa M, et al. Efficacy of a fourth dose of COVID-19 mRNA vaccine against omicron. N Engl J Med. 2022;386:1377–1380. - PMC - PubMed
    1. Marking U, Bladh O, Havervall S, et al. 7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection. Lancet Infect Dis. 2023;23:150–152. - PMC - PubMed

Publication types

Substances